No­var­tis strikes a $103M deal for blue­bird's PRV — if it wins one

An FDA de­ci­sion on blue­bird bio’s third gene ther­a­py isn’t ex­pect­ed un­til De­cem­ber, but No­var­tis has al­ready locked up a po­ten­tial pri­or­i­ty re­view vouch­er that might re­sult.

No­var­tis agreed to pur­chase blue­bird’s Rare Pe­di­atric Dis­ease PRV for $103 mil­lion, should the FDA grant one, blue­bird an­nounced Mon­day. Its gene ther­a­py lovotibeglo­gene au­totem­cel (lo­vo-cel) is cur­rent­ly un­der FDA re­view for sick­le cell dis­ease in pa­tients 12 years and old­er, with a de­ci­sion an­tic­i­pat­ed by Dec. 20.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA